Background: HIV-positive individuals (HIVþ) on antiretrovirals commonly take enough other medications to cross a threshold for polypharmacy but little is known about associated outcomes. We asked whether non-antiretroviral polypharmacy is associated with hospitalization and mortality and whether associations differ by HIV status.
Introduction
In observational studies of the general population, the use of more than five concurrent medications constitutes polypharmacy [1] . In this group, polypharmacy is widespread and associated with adverse drug events, inappropriate prescribing, falls, cognitive compromise, hospitalization, and mortality [2, 3] . Combination antiretroviral treatment for HIV infection with three or more medications dramatically improves morbidity and extends survival but requires life-long treatment. Yet, antiretrovirals are known to have many drug-drug interactions with commonly co-prescribed medications [4, 5] . If two or more non-antiretroviral medications are added, HIVpositive individuals (HIVþ) would conventionally cross the threshold for polypharmacy [6] . Yet, no group has established a threshold for non-antiretroviral polypharmacy among HIVþ based on associations with hospitalization or mortality or compared associations with demographically similar uninfected individuals. Instead, studies characterizing non-antiretroviral polypharmacy in HIVþ have considered only potentially inappropriate medications because of drug-drug interactions or side effects [4, 5, [7] [8] [9] [10] .
Of special note, non-antiretroviral medications are prescribed to treat comorbid health conditions, as prophylaxis, or to treat adverse effects of antiretrovirals. Severity of illness because of comorbid conditions, not polypharmacy, may explain observed associations (confounding by indication) [11] . Although only a randomized trial can completely address this issue, adjusting for severity of illness using an accurate and validated prognostic index can help. However, few studies in the general population and no study among HIVþ, have adjusted for severity of illness. In the general population, the studies that have adjusted for severity of illness have used self-reported functional status, health status, or comorbid conditions [11, 12] . Such measures are often based on self-report or administrative diagnostic codes and provide limited discrimination of mortality [13] [14] [15] . No prior study associating polypharmacy with health outcomes, among those with or without HIV infection, has used a well validated, highly discriminating, index to comprehensively adjust for severity of illness.
On the basis of routine clinical laboratory data, the Veterans Aging Cohort Study (VACS) Index has been widely validated as a highly discriminating measure of severity of illness [16, 17] . It accurately and reproducibly predicts all-cause mortality among those with and without HIV infection and is associated with hospitalization [18] [19] [20] . In this study, we compare nonantiretroviral polypharmacy, considering both more than two and at least five thresholds, between HIVþand demographically matched uninfected patients to determine: associated unadjusted and adjusted risk of hospitalization and mortality, whether risks differ by HIV status, and if a dose-response association exists between the number of non-antiretroviral medications and risk of hospitalization or mortality.
Methods

Study overview
We conducted a prospective analysis of the VACS described previously [21] . 
Study population
We included HIVþ individuals receiving ART and uninfected individuals who were receiving at least one prescription medication from the VA in fiscal year 2009. HIVþ individuals were considered to be on ART if they were prescribed three or more antiretroviral agents, excluding low-dose ritonavir. We required uninfected individuals to be on at least one VA dispensed medication to insure that they were obtaining medications from the VA. Among patients alive at the end of fiscal year 2009, we excluded patients who had any cancer diagnosis except nonepithelial skin cancer (n ¼ 1874) as their severity of illness may not be adequately reflected in the VACS Index; ambiguous HIV status (n ¼ 99) to make a clear comparison between HIVþ and uninfected individuals; HIVþ individuals who were not virally suppressed (>400 HIV-1 RNA copies/ml) in the last 6 months of baseline fiscal year 2009 (n ¼ 9018) -we sought to study polypharmacy among those on successful ART; 4) no VACS index score (n ¼ 4085); and on more than 15 medications to eliminate highly leveraged observations (n ¼ 534, 1% of the analytic sample).
Nonantiretroviral medication count and polypharmacy
We determined receipt of all outpatient preparations (i.e. oral, inhaled, or injectable) of medications dispensed through the VA using prescription pharmacy fill/refill data [21] . We excluded prescriptions classified as diagnostic supplies (e.g. glucose test strips); emollients; eye washes and lubricants; soaps, shampoos and soap-free cleaners; mouthwashes; sun protectants and screens; irrigation solutions; ceruminolytics; deodorants and antiperspirants; and contact lens solutions from analyses. Our analysis was restricted to medications, which were filled on a chronic basis, defined as at least 90 consecutive days allowing for a 30-day refill window, consistent with previous definitions [22] .
Days of medication receipt were calculated based on prescription information, assuming the prescription was taken as directed. Patients may have started a medication before fiscal year 2009 or continued them after fiscal year 2009; we captured only days supplied within fiscal year 2009. Medications were categorized according to VA class. We calculated the mean number of unique nonantiretroviral long-term medications received by each patient during fiscal year 2009 by summing the number of days supplied for each medication and dividing the total by 365 days. Each component of co-formulated medications was counted separately.
Adverse health outcomes
Hospitalization was identified from the VA (including fee-based) and Center for Medicare and Medicaid Services (CMS). All-cause mortality was obtained from the VA Vital Status File, which includes data from inpatient records, the VA Beneficiary Identification Records Locator Subsystem (BIRLS), Social Security Administration, and CMS. Excellent reliability and validity of the Vital Status File has been established by comparison with the National Death Registry [23] . We conducted surveillance for hospitalization and mortality; time to event was calculated from the start of fiscal year 2010 to the date of first event or censored at the end of fiscal year 2015.
Covariates Demographic variables included age, race/ethnicity, and sex. Diabetes mellitus status was determined based on laboratory and pharmacy data [24] . BMI and blood pressure (uncontrolled hypertension) were obtained from clinic visit records. Controlled hypertension was based on a normal blood pressure and receipt of an antihypertensive. Hepatitis C virus (HCV) status was considered positive if a patient had a positive HCV antibody test or HCV RNA or ICD-9 codes for HCV infection. We determined the presence of other comorbid medical and psychiatric diseases by requiring at least one inpatient or two outpatient ICD-9 codes [25] .
We used the VACS Index to adjust for disease severity [16] [17] [18] [19] [20] . The VACS Index is a physiologic score predicting risk of all-cause mortality initially developed among HIVþ individuals that integrates data on age; HIV biomarkers (HIV-1 RNA viral load; CD4 cell count); and non-HIV biomarkers (hemoglobin, hepatitis C; FIB-4 to assess liver function, and estimated glomerular filtration rate to assess renal function). It has also been validated in uninfected individuals [20] . Potential scores range from 0 to 164, with higher scores being associated with a greater risk of mortality. A five-point increase in VACS Index score is associated with a 20% increase in 5-year mortality risk (e.g. hazard ratio of 1.2). Scores were determined using laboratory values closest to the end of fiscal year 2009.
Analyses
In bivariate analyses, we evaluated characteristics of HIVþ and uninfected individuals associated with non-antiretroviral polypharmacy using a chi-square test and calculating odds ratios for more than two and at least five nonantiretroviral polypharmacy. We used Cox proportional hazard models to determine the association between nonantiretroviral medication count (and >2 and !5 thresholds for non-antiretroviral polypharmacy), hospitalization, and mortality adjusted for disease severity (as measured by the VACS Index) and demographic factors. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Role of the funding source
The funding source played no role in this analysis.
Results
Sample characteristics
During fiscal year 2009 (baseline), 9473 HIVþ were on antiretrovirals with suppressed HIV-1 RNA and 39 812 uninfected individuals were receiving at least one medication from VA pharmacy. Overall, the sample was predominantly 50-64 years of age (Table 1 , 64, 64%), racially and ethnically diverse (41% white, 46% black, 9% Hispanic), predominantly men (98%) and demographically similar by HIV status. Both HIVþ and uninfected were actively engaged in care (mean visits/year: HIVþ 2.1, uninfected 1.9). Among HIVþ individuals, median CD4 count was 515 (IQR 347, 720). By design, all HIVþ individuals were on antiretrovirals (60% protease inhibitor-based, 40% nonnucleoside reverse transcriptase inhibitors, and <0.1% on an Integrase inhibitor) and had HIV-1 RNA 400 copies/ml or less.
Several common comorbidities were similarly distributed among HIVþ and uninfected individuals included current or past smoking (Table 1 , 69%), hypertension (64%), hyperlipidemia (40%), and psychiatric diagnoses (27%). HIVþ individuals experienced more HCV infection (35% HIVþ, 15% uninfected). Uninfected individuals were more likely to experience chronic pain (49% uninfected, 36% HIVþ), diabetes (33% uninfected, 22% HIVþ), morbid obesity (BMI > 35, 19% uninfected, 5% HIVþ), or a psychiatric diagnosis (29% uninfected, 20% HIVþ). HIVþ individuals demonstrated greater severity of illness than uninfected. HIVþ individuals had higher VACS Index scores (Table 1, 24 vs. 18) . During the observation period HIVþ were also more likely than uninfected individuals to be hospitalized (58 and 55%) or die (17 and 14%).
Common non-antiretroviral medications were similar in both groups. Among HIVþ and uninfected individuals, respectively, the 10 most commonly received medication classes were lipid-lowering medications ( (11 and 22%) . Of note, longterm prescription opioids (17 and 21%) were commonly prescribed to both HIVþ and uninfected individuals and proton pump inhibitors, by far the most common gastric medications, were also commonly used for more than 90 days (19 and 32%), respectively. The distribution of nonantiretroviral medication count was fairly similar among HIVþ and uninfected with HIVþ having slightly lower counts (Fig. 1) . Median (5th and 95th) non-antiretroviral medication count was 3 (1, 10) among HIVþ, and 4 (1, 11) among uninfected.
Characteristics associated with nonantiretroviral polypharmacy In bivariate analyses, characteristics of HIVþ and uninfected individuals associated with non-antiretroviral polypharmacy, whether defined as more than two or at least five non-antiretrovirals, were similar (Table 2) . Older age was strongly associated with polypharmacy. Those 50-64 were twice as likely, and those 65 and over, nearly three times as likely, to experience non-antiretroviral polypharmacy compared with those less than 50 years of age. Although HIVþ men were as likely as HIVþ women to experience non-antiretroviral polypharmacy, uninfected men were 20-40% more likely than uninfected women to experience polypharmacy. Whites were about 20% more likely than other racial groups to experience non-antiretroviral polypharmacy. Conditions that more than doubled the odds of non-antiretroviral polypharmacy in both groups included: hypertension, diabetes, coronary artery disease, chronic obstructive pulmonary disease, and psychiatric diagnoses. Some common minor conditions doubled the probability of non-antiretroviral polypharmacy including: hyperlipidemia and gastroesophageal reflux. Interestingly, HCV infection, alcohol, and drug use disorders were more associated with polypharmacy among HIVþ than uninfected ($30-60% increased risk for HIVþ versus 10% for uninfected). 
Nonantiretroviral polypharmacy and hospitalization
In unadjusted analyses, more than two and at least five non-antiretroviral polypharmacy was associated with increased risk of hospitalization ( In unadjusted and adjusted analyses, compared with those on two or fewer non-antiretroviral medications, non-antiretroviral polypharmacy demonstrated a doseresponse association with risk of hospitalization among HIVþ and uninfected (Fig. 2) . Whenever nonantiretroviral medication count was modeled as a continuous variable (Table 4) , we observed an 8% incremental increased risk of hospitalization with each Table 2 . Association of characteristics with nonantiretroviral polypharmacy (more than two and at least five medications).
Polypharmacy prevalence (%)
Odds ratio for polypharmacy 
Nonantiretroviral polypharmacy and mortality
In unadjusted analyses, more than two non-antiretroviral polypharmacy was associated with 68% increased risk of mortality among HIVþ (Table 3 , >2: hazard ratio 1.68, 95% CI 1.50-1.89) and a 99% increased risk among uninfected individuals (hazard ratio 1.99, 95% CI 1.86-2.14, P for interaction ¼ 0.01). Using the at least five threshold in unadjusted analysis, polypharmacy was associated with an 83% increased risk of mortality in both HIVþ and uninfected (P for interaction ¼ 0.1, !5: hazard ratio : 1.83, 95% CI 1.75-1.82).
In fully adjusted models, more than two non-antiretroviral polypharmacy was associated with a 20% increased risk of mortality among HIVþ (>2: hazard ratio 1.20, 95% CI 1.07-1.36) and a 49% increased risk among uninfected (>2: hazard ratio 1.49, 95% CI 1.39-1.60, P for interaction ¼ 0.002). The fully adjusted model of at least five non-antiretroviral polypharmacy demonstrated a 43% increased risk of mortality among HIVþ and uninfected (!5: hazard ratio 1.43, 95% CI 1.36-1.50, P for interaction ¼ 0.1).
In unadjusted and adjusted analyses, compared with those on two or fewer non-antiretroviral medications, we observed a dose-response association between nonantiretroviral polypharmacy and risk of mortality among HIVþ and uninfected (Fig. 2) . Whenever non-antiretroviral medication count was modeled as a continuous variable (Table 4) , we observed a 5% increase in risk of mortality with each additional non-antiretroviral medication among HIVþ (hazard ratio 1.05, 95% CI 1.03-1.06), and a 7% increase among uninfected (hazard ratio 1.07, 95% CI 1.06-1.07).
Discussion
In this large cohort of HIVþ and demographically similar uninfected individuals, non-antiretroviral polypharmacy All bivariate odds ratios significant at P < 0.001 except as noted. HIVþ, sex P ¼ 0.98, uninfected, drug abuse and dependence P ¼ 0.006. ARV, antiretroviral therapy. Hazard ratios are expressed in terms of non-ARV polypharmacy using a more than two or a at least five medication threshold. Fully adjusted models were adjusted for VACS Index score, age, sex, and race/ethnicity. ARV, antiretroviral therapy; CI, confidence interval. a Interaction between polypharmacy, HIV, and hospitalization was not significant in any model. demonstrates a dose-response association with hospitalization and mortality and neither severity of illness nor demographic factors explain these associations. Short of a randomized trial, these results provide important evidence that non-antiretroviral polypharmacy contributes to adverse health events among those aging with and without HIV infection.
Our study extends prior literature in several ways [2] [3] [4] [5] [7] [8] [9] [10] . We had direct access to pharmacy-dispensing data in a national system with generous pharmaceutical coverage. As patients fail to fill many prescriptions, data on medication orders (prescriptions) are less informative than dispensing data. We are also the first to consider the association of non-antiretroviral polypharmacy with actual clinical outcomes among HIVþ rather than potential drug interactions or other possible adverse effects. We consider adverse associations with polypharmacy using two potential thresholds for non-antiretroviral polypharmacy (>2 and !5) and as a continuous measure (non-antiretroviral medication count). We are the first to compare health outcomes associated with Hazard ratios are expressed in terms of risk associated with each additional non-ARV medication. Fully adjusted models were adjusted for VACS Index score, age, sex, and race/ethnicity. ARV, antiretroviral therapy; CI, confidence interval. a P for interaction between polypharmacy, HIV, and hospitalization was not significant (adjusted model P ¼ 0.99).
b P for interaction between polypharmacy, HIV, and mortality was significant (adjusted model P ¼ 0.04).
polypharmacy among HIVþ with demographically similar uninfected individuals. Our hospitalization data is completely parallel among HIVþ and uninfected and include events occurring within the VA system, fee for service, and care supported by other United States governmental sources (Medicare and Medicaid). Similarly, VA mortality data are very complete [23] . Finally, a major innovation of our study is our ability to adjust for severity of illness using a widely validated and accurate physiologic index.
Although many have suggested that the association between polypharmacy and adverse health outcomes is because of confounding by indication -sicker patients take more medications -our analysis suggests otherwise. The VACS Index is a widely validated, highly discriminating, physiologic index predictive of hospitalization and mortality among veterans with and without HIV infection [16] [17] [18] [19] [20] . The VACS Index meets or exceeds the discrimination of prior indices validated among older individuals [26] . Yet, the correlation between the VACS Index and non-antiretroviral polypharmacy was only moderate and full adjustment for the Index, age, race/ethnicity, and sex did not 'explain' the association between non-antiretroviral polypharmacy and hospitalization or mortality. After these adjustments, nonantiretroviral polypharmacy remained independently associated with hospitalization and mortality in a doseresponse manner. Thus, although demographic factors, especially age, and severity of illness are associated with polypharmacy and health outcomes, neither appear to be major confounders of the association between polypharmacy and adverse health outcomes.
Instead, particular diagnoses (not all of which are associated with hospitalization or mortality), individual provider styles, and other factors not directly related to prognosis, may contribute more to polypharmacy than previously appreciated. For example, diagnoses of hyperlipidemia or gastroesophageal reflux roughly doubled the probability of non-antiretroviral polypharmacy and medication-controlled hypertension increased the probability of nonantiretroviral polypharmacy more than five times. Importantly, over 6 years of observation, none of these conditions conferred an increased risk of mortality independent of non-antiretroviral medication count, VACS Index score, and demographic factors (data not otherwise shown). Of note, these associations were similar by HIV status suggesting similar factors drive polypharmacy among those with and without HIV infection and suggesting potential targets for future intervention.
Likely mechanisms of injury from polypharmacy among HIVþ and uninfected individuals include cumulative toxicity, side effects, and drug-drug interactions [2, 3] . As those with HIV age, the problem of adverse health outcomes because of non-antiretroviral polypharmacy may grow. Although antiretrovirals extend survival, they must be taken for the rest of the patient's life. antiretroviral initiation often precipitates polypharmacy a decade earlier for HIVþ than uninfected individuals [6] . Antiretrovirals interact with a wide range of common medications including lipid-lowering agents, antihypertensives, antidepressants, proton-pump inhibitors, and prescription opioids [27] . Additionally, compared with uninfected individuals, HIVþ had higher VACS Index scores indicating increased physiologic frailty and susceptibility to drug injury.
For example, 18% of HIVþ in our sample were on a proton-pump inhibitor for more than 90 days. Most protease inhibitors and several nonnucleoside reverse transcriptase inhibitors interact with proton-pump inhibitors [5] . In most circumstances, proton-pump inhibitors should not be prescribed for more than 30 days. Further, proton-pump inhibitors are associated with a growing list of serious adverse effects to which HIVþ may have increased susceptibility including fragility fractures, cognitive difficulties, and malabsorption [28] .
Some might argue that comorbid conditions among HIVþ on antiretrovirals are undertreated. As observed in this study, non-antiretroviral medications are less commonly dispensed to HIVþ than to uninfected individuals. For example, HIVþ were less likely to receive lipidlowering therapy for indicated cardiovascular disease prevention [29] . Whether this reflects a primary focus on antiretrovirals, a judicious under use related to concerns about polypharmacy; lack of comfort with non-HIV care, or clinical oversight remains to be determined. Hundreds of trials have been conducted considering whether adding a specific medication or set of medications improves outcomes, few interventions to reduce polypharmacy (deprescribe) have been tested. Most deprescribing trials failed to reduce medications because they are typically required to comply with disease-specific guidelines developed without consideration of multimorbidity or polypharmacy [30] . For every medication to treat a symptom that the trialists stopped, medications for primary and secondary prevention of disease were added. Only a randomized trial can determine whether deprescribing reduces hospitalization or mortality among those exposed to polypharmacy. Our analyses offer stronger evidence than previously reported, either among HIV infected or the general population, that polypharmacy may cause excess hospitalization and mortality. This evidence may help inform the equipoise necessary for randomized trials of deprescribing among patients with non-antiretroviral polypharmacy.
Substantial work is needed to determine how best to proceed. Although many studies in uninfected populations cite five medications as a critical threshold, no study has established the definitive threshold for non-antiretroviral polypharmacy. An important strength of our analyses is that we considered two thresholds for non-antiretroviral polypharmacy (>2 and !5) as well as analyzing nonantiretroviral medication count as a continuous variable. Our analyses suggest that harms accrue in a monotonically increasing manner with three or more non-antiretroviral medications for HIVþ and uninfected individuals.
Thresholds for injury from polypharmacy likely depend on the specific regimen, the individual's underlying physiologic injury, and genetic susceptibility. Sophisticated computer models will likely be needed, incorporating knowledge such as that contained in databases of the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to account for what is known about drug-drug and drug and common substance use interactions. Current criteria such as Beers or START/STOPP were developed among uninfected individuals over 65 years of age, and evidence for the effectiveness of these criteria in avoiding actual adverse health outcomes is contradictory and limited. HIVþ on lifelong antiretrovirals, may continue to use alcohol and other substances that may also interact with their medications, and may require special consideration.
Beyond nonrandom assignment, our findings should be interpreted in light of the following limitations. We did not consider specific antiretroviral classes or agents, the number of antiretrovirals in use, or the association of specific non-antiretroviral medication classes or individual non-antiretroviral medications with hospitalization or mortality. We did not consider 'potentially inappropriate' medications in light specific antiretrovirals, advanced age, other non-antiretroviral medications or classes, or the use of alcohol. We did not study the effect of adding or subtracting a medication. Such analyses are needed, but are beyond the scope of this study. Our non-antiretroviral medication count was based on medications dispensed within the US Veterans Affairs Healthcare System (VA) and do not reflect outside prescriptions, over the counter, or complimentary medications making our measures of non-antiretroviral medication count and polypharmacy conservative. Although HIVþ in our sample were demographically similar to uninfected, the strict 1 : 2 matching employed in the VACS cohort was not preserved after the exclusions required for this analysis were applied. Finally, our analysis should be replicated in other healthcare systems.
Conclusion
Accounting for demographics and severity of illness, both HIVþ and uninfected individuals experience increasing risk of hospitalization and mortality when exposed to increasing counts of non-antiretroviral medication. Future research is needed to determine the impact of eliminating medications not essential for quality of life and survival among those aging with HIV infection.
